Please login to the form below

Not currently logged in
Email:
Password:

osimertinib

This page shows the latest osimertinib news and features for those working in and with pharma, biotech and healthcare.

Cancer drugs and China sustain AZ’s return to growth

Cancer drugs and China sustain AZ’s return to growth

The star in oncology for AZ is non-small cell lung cancer (NSCLC) therapy Tagrisso (osimertinib), which grew 95% to $1.86bn last year, thanks to a move up the treatment

Latest news

More from news
Approximately 5 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...
Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...

Infographics